No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MCRB241220C500
- 0.44
- +0.02+4.76%
15min DelayClose Dec 20 16:00 ET
0.44High0.44Low
0.44Open0.42Pre Close3 Volume225 Open Interest0.50Strike Price132.00Turnover0.00%IV2.73%PremiumDec 20, 2024Expiry Date0.42Intrinsic Value100Multiplier-1DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence
Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction
Express News | Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025
Express News | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference